Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Conditions:   Colorectal Adenocarcinoma;   Gastric Adenocarcinoma;   Pancreatic Adenocarcinoma;   Bile Duct Carcinoma;   Hepatocellular Carcinoma;   Esophageal Carcinoma;   Gastrointestinal Cancer
Intervention:   Drug: CGX1321
Sponsors:   Curegenix Inc.;   Guangzhou Curegenix Co. Ltd.
Recruiting

https://ift.tt/2HrnU6e